Top FDA Official Slams Federal Drug Scheduling System For Blocking CBD Research | Marijuana Moment

  • Speaking at the National Industrial Hemp Council’s 2019 Hemp Business Summit , FDA Principal Associate Commissioner for Policy Lowell Schiller gave an extensive overview of the agency’s role in regulating cannabis products, repeatedly stressing that FDA is ” excited” about cannabidiol’s potential.
  • The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law.
  • Loosening federal restrictions by rescheduling it could help, but ” Congress could even choose to remove marijuana from the CSA altogether, in the same way it exempted alcoholic beverages and tobacco from the statute’s coverage in the first instance,” ABA wrote .
  • ABA noted that the Drug Enforcement Administration (DEA) announced in 2016 that it is accepting applications for additional cannabis manufacturers, which could bolster research, for example.

Read full article: